Oxford BioMedica set to receive €9 million milestone payment

Oxford BioMedica Plc said that it has reached the first development milestone in its collaboration with Sanofi-Aventis to produce a cancer immunotherapy product, leading to a payment of €9 million. The product, TroVax, targets the tumour antigen 5T4 which appears in a wide range of solid tumours.